NCT06932484 Delta Variation to Guide Hemodynamic Optimization
| NCT ID | NCT06932484 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Hemodynamic MAP Stability |
| Study Type | INTERVENTIONAL |
| Enrollment | 104 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 104 participants in total. It began in 2025-06-01 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
intraoperative hemodynamic optimization will be based on the percentage of variation of the parameters
Eligibility Criteria
Inclusion Criteria: All patients \> 18 years old scheduled for major abdominal Exclusion Criteria: Body Mass Index \> 35 kg/m2 Pregnancy Refusal to sign written informed consent Urgent and/or emergency surgery
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06932484 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hemodynamic MAP Stability. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06932484 currently recruiting?
Yes, NCT06932484 is actively recruiting participants. Contact the research team at andrea.russo@policlinicogemelli.it for enrollment information.
Where is the NCT06932484 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT06932484 clinical trial?
NCT06932484 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 104 participants.